Real-world safety of vericiguat as a fifth-line agent in heart failure: a pharmacovigilance study of quintuple therapy

Background

Vericiguat, a novel soluble guanylate cyclase (sGC) stimulator, is indicated for high-risk worsening heart failure (HF). However, its real-world reporting profile when added to contemporary quadruple guideline-directed medical therapy (GDMT)-effectively creating a "quintuple" regimen-remains largely unexplored, particularly regarding cardiorenal and hematologic adverse-event reporting patterns.